Abstract
Background Combinations of common drugs may, when taken together, have unexpected effects on cancer. It is not feasible to test for all combination drug effects in clinical trials, but in the real world, drugs are frequently taken in combination. Then, there may be undiscovered effects protecting users from cancer–or increasing their risk. By analyzing massive health claims data containing numerous people exposed to drug combinations, we have an opportunity to evaluate the association of drug combinations with cancer risk. Discovering these effects can not only contribute to prevention of cancer, but also suggest new uses for combinations to prevent or treat cancer.
Method Our approach emulates a randomized trial where one arm would have been assigned to take a particular drug alone, while the other arm takes it together with a second drug. Because discovery of associations from observational data is prone to spurious results due to confounding, we develop strategies to distinguish confounding from biomedically relevant findings.
Results This tactic allows us to systematically assess effects across over 9,000 drug combinations, on all common cancers. Through multiple sensitivity analyses we identify a robustly supported beneficial drug combination that may synergistically impact lipid levels to reduce risk of cancer.
Conclusions This study demonstrates the importance of considering confounding factors in drug-wide studies. But, we also show that our method is able to uncover associations with robust support.
Impact Searching for combinations of factors impacting cancer is crucial, but these effects can only be systematically discovered through observational data analysis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
K01ES028055
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only deidentified publicly available human claims data from MarketScan IBM and has been deemed to be not human subjects research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Additional information: This work was supported by K01ES028055 the National Institutes of Health to RDM.
The authors declare no conflicts.
Text has been edited for clarity and figures merged for ease of viewing.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
